When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?
Live prediction market odds for When will FDA announce Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List?. Compare prices across Kalshi and Polymarket.
Listed Updated Expected to settle by
Traders give Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026? about a 6.8% chance. Compare prices from Kalshi and Polymarket. The largest cross-platform price difference is 0.5 percentage points.
Official settlement criteria, resolution sources, and edge cases across Kalshi.
KalshiIf the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
The outcomes listed above show how traders are pricing this question. Compare outcome prices from Kalshi, Polymarket in one place. Each price reflects the market’s implied probability, not a guaranteed result.
The latest available prices are Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026?: 6.5¢ on Kalshi, 7.0¢ on Polymarket. Prices are quoted in cents per $1 share. Check the venue for executable prices and available liquidity.
The largest price difference shown across venues is 0.5 percentage points. Venues have different traders, liquidity and fees, so their prices can differ. A price gap alone does not establish an executable arbitrage opportunity; compare settlement rules and the actual buy and sell prices.
For example, Will the FDA reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by December 31, 2026? at 6.8¢ implies about a 6.8% chance. For a standard $1 contract, a share pays $1 if its outcome settles as correct and $0 if it settles as incorrect. A winning share bought at 40¢ earns 60¢ before fees. Check each venue’s settlement rules, fees and eligibility before trading.
